EP1350101A2 - Preparation tissulaire ou cellulaire morphometrique - Google Patents

Preparation tissulaire ou cellulaire morphometrique

Info

Publication number
EP1350101A2
EP1350101A2 EP01985910A EP01985910A EP1350101A2 EP 1350101 A2 EP1350101 A2 EP 1350101A2 EP 01985910 A EP01985910 A EP 01985910A EP 01985910 A EP01985910 A EP 01985910A EP 1350101 A2 EP1350101 A2 EP 1350101A2
Authority
EP
European Patent Office
Prior art keywords
weight
cells
tissue
morphometric
cell preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP01985910A
Other languages
German (de)
English (en)
Inventor
Carolin Schmidt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP1350101A2 publication Critical patent/EP1350101A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082Supracellular entities, e.g. tissue, organisms
    • G01N33/5088Supracellular entities, e.g. tissue, organisms of vertebrates
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells

Definitions

  • the invention relates to a morphometric tissue or cell preparation which can be obtained by carrying out the following process steps: a) cells or tissue are cultivated in a matrix for a defined time under defined conditions, b) after the defined time has elapsed, the cells or cells are cultured Tissue-containing matrix incubated with a staining solution.
  • the invention further relates to a manufacturing method for such a preparation and uses thereof.
  • the invention relates to a fixing and staining solution for use in such a method.
  • a morphometric tissue or cell preparation is treated in a manner that allows recognition of the
  • Form formation of cellular structures or of tissue structures allowed. It is essential here that shapes, for example shapes of cells and / or cell components and / or tissues, are made recognizable by means of contrast-forming methods. Detection can be carried out by observation using various optical methods, in the simplest case using normal light microscopy. Often, certain shape features are counted as part of the recognition, which are usually correlated with certain cellular processes. The detection can be carried out visually by the human eye, with a person viewing then, for example, identifying sought structures and possibly counting them using the
  • Pattern recognition system which can then automatically count.
  • a recording can be carried out photographically or electronically, for example using CCD elements.
  • the methodology is used to determine what influence the defined cultivation conditions have on morphogenesis.
  • the expression of the defined cultivation conditions therefore also includes, in particular, non-natural or non-standard conditions, which are characterized, for example, by adding one or more prospective active ingredients to a standard medium. It is understood that the
  • the coloring solution serves to highlight the shaping features of interest in contrast.
  • the average person skilled in the art can easily select the dye according to the forms of interest (for example, basic dyes bind to acidic cell structures, such as DNA in the nucleus or RNA in the ribosomes; acidic dyes preferably bind to basic ones
  • Dye then form the colored areas, while areas in which there are no or fewer binding sites for the dye are not or only weakly colored areas. Ultimately, this is the mechanism of contrast formation.
  • a method of the type mentioned at the outset is, for example, from the literature reference Leclere, P., Neuroscience: 82, 545-548, 1998.
  • ganglion cell explants were treated with a nerve growth factor or cultured in the presence thereof, and then this was induced
  • Neurite growth analyzed morphometrically. Staining was carried out using dye-labeled or dye-labeled antibodies. It is therefore an antigen-dependent staining method. specific
  • Stains of this type are only suitable for very thin matrices. However, it is often desirable to use distinctly three-dimensional matrices or cultures, in which case a sufficiently homogeneous antigen-dependent staining is difficult or impossible. In addition, antigen-dependent staining methods are time-consuming and expensive.
  • the invention teaches a morphometric tissue or
  • Cell preparation which can be obtained by carrying out the following process steps: a) cells or tissues are cultivated for a defined time under defined conditions in a three-dimensional matrix, b) after the defined time has elapsed, the matrix containing the cultivated cells or tissues is treated with a Fixing and staining solution containing an aldehyde and, optionally an alcohol, and an antigen-unspecific stain incubated. This can be followed by a washing process step, for example with water.
  • An antigen-nonspecific colorant is a dye that can bind non-specifically to molecules or molecular classes of a cell or a tissue solely because of its acidic or basic groups, but also through redox processes. Binding to virtually all structures of cells or tissue can also take place.
  • Antibodies are not used.
  • the aldehyde and possibly the alcohol brings about a reliable fixation of structures of the cells or of the tissue by a variety of immobilizing reactions with intrinsically mobile molecules of the cells or of the tissue, for example by Mannich reactions.
  • this includes preparations whose spatial extent in all three spatial directions is a multiple of the spatial extent of the cultivated cells, for example equal to or more than 2 times, preferably more than 10 times, up to more than 100 times , It is achieved with the invention that this is pronounced three-dimensional line or tissue preparations are stable and permanently fixed and at the same time very high-contrast images are obtained using the simplest methods, for example simple light microscopy. Only one treatment with the fixing and staining solution is necessary, ie it is a "one-step” method. In addition, pronounced three-dimensional specimens can be fixed and stained easily, while specific staining of such specimens using antibody-based methods is hardly possible, if at all. Pronounced three-dimensional preparations are those that do not only have a minimal thickness (cuts), but rather can have thicknesses from 0.2 ⁇ m to 20 mm, in particular 0.2 mm to 20 mm.
  • the fixing and staining solution contains water, optionally a water-miscible organic solvent, and
  • the aqueous saline solution reliably prevents changes in the shape of cells or tissue, for example due to osmosis, in the course of fixation and staining.
  • the fixing and staining solution can contain the following components: A) 0.5-35% by weight, preferably 1-2% by weight, aldehyde, B) 0.01 to 10% by weight, preferably 0 , 3 - 0.6% by weight, colorant, C) 0 - 90% by weight, preferably 30 - 50% by weight, of one or more water-miscible organic solvents,
  • E 0-5% by weight, preferably 0.1-1% by weight, of common salt, the sum of the proportions of components A) to E) always giving 100% by weight, and the ratio of the proportions by weight of Components E: D are in the range from 1: 1000 to 1: 100, preferably corresponds to the ratio by weight of a physiological saline solution.
  • the invention also relates independently to such a fixing and staining solution.
  • the duration of the incubation in stage b) can be in the range from 0.5 to 24 h, preferably in the range from 1 to 10 min.
  • the incubation in stage b) can be carried out at a temperature from 0 ° C. to 60 ° C., preferably from 0 ° C. to 40 ° C.
  • the water-miscible organic solvent can be selected from the group consisting of "Cl-10 alkanols with 1-3 OH groups, Cl-10 alicyclic alcohols with 1-3 OH groups, Cl to C10 aromatic alcohols, and mixtures of such substances ". Ethanol is preferred.
  • the colorant can be selected from the group consisting of "crystal violet, amido black, cresyl violet, and mixtures of such substances”.
  • the matrix can be selected from the group consisting of "extracted natural extracellular matrices of various origins, in particular from rat tails or pig skin, their main components, in particular collagen, laminin, fibronectin, and mixtures of these substances".
  • the aldehyde can be selected from the group consisting of "Cl to C10 alkanaldehydes, Cl to C10 alicyclic aldehydes, aromatic Cl to C10 aldehydes, and mixtures of such aldehydes". Formaldehyde and paraformaldehyde are preferred.
  • the individual cells or complex tissues of the preparation can be or consist of, for example, tumor cells, nerve cells, glial cells, muscle cells, blood cells. In the area of drug binding, the cells are optimally (but not necessarily) human cells.
  • the invention further teaches a method of manufacture of a morphometric tissue or cell preparation, the following process steps being carried out: a) cells or tissues are cultivated over a defined time under defined conditions in a pronounced three-dimensional matrix, b) after the defined time has elapsed, the matrix containing the cultivated cells or tissue is included a fixing and staining solution containing an aldehyde and an antigen-unspecific stain.
  • a) cells or tissues are cultivated over a defined time under defined conditions in a pronounced three-dimensional matrix
  • the matrix containing the cultivated cells or tissue is included a fixing and staining solution containing an aldehyde and an antigen-unspecific stain.
  • the invention furthermore teaches the use of a morphometric tissue or cell preparation according to the invention for the morphometric analysis of cellular processes caused by cultivation conditions.
  • defined conditions are set from which a certain morphogenetic effect is expected. This is then evaluated and correlated with the defined conditions, if necessary semi-quantitative or quantitative.
  • This also includes the use of a morphometric tissue or cell preparation according to the invention in a process for finding active substances, the active substance being used in step a), with the cells or tissue being subsequently recorded in step b) by means of, for example, an optical microscope, wherein the image obtained is preferably evaluated by means of an image recognition system, the result of the evaluation being assigned to the active substance, and where appropriate the method being repeated for different active substances and the results of the evaluation obtained for different active substances being compared with one another.
  • a quantitative, or at least semi-quantitative, statement is obtained regarding the orphogenetic effect caused by the investigated active substances.
  • the cells can, for example, ganglion cells, especially dorsal Schuwurzelganglien, be, the evaluation then z. B. includes the detection of newly formed neurites.
  • the cells can also be tumor cells, the evaluation then comprising, for example, the detection of emigrated cells.
  • the cultivation was then carried out for several hours in a culture medium containing nerve growth factor.
  • the cultivation was ended by aspirating the culture medium from the gel and by the following staining and fixing step.
  • Example 1 The gel obtained in Example 1 was then treated with a filtered fixing and staining solution. This contained: 2.42 g crystal violet, 162 ml ethanol (100%), 323 ml distilled water, 16 ml formaldehyde (35%, balance water), and 0.8 g NaCl. The treatment was carried out for 5 min. at 20 ° C. Then it was washed with water.
  • the washed gel was then placed on a light microscope (Zeiss Axiovert, bright field, magnification of the objective lOx) and a detailed picture was taken, as shown in FIG. 1.
  • a light microscope Zeiss Axiovert, bright field, magnification of the objective lOx
  • FIG. 1 In the figure 1 below is the edge of the

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une préparation tissulaire ou cellulaire morphométrique qui peut être obtenue grâce à la mise en oeuvre des étapes suivantes: a) des cellules ou des tissus sont cultivés pendant un temps défini dans des conditions définies dans une matrice tridimensionnelle; b) après écoulement du temps défini, la matrice contenant les cellules ou tissus cultivés est incubée avec une composition de fixation et de coloration contenant un aldéhyde ainsi qu'un colorant non antigène-spécifique.
EP01985910A 2001-01-09 2001-12-20 Preparation tissulaire ou cellulaire morphometrique Withdrawn EP1350101A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10101319 2001-01-09
DE10101319A DE10101319A1 (de) 2001-01-09 2001-01-09 Morphometrisches Gewebe- oder Zellpräparat
PCT/EP2001/015055 WO2002055680A2 (fr) 2001-01-09 2001-12-20 Preparation tissulaire ou cellulaire morphometrique

Publications (1)

Publication Number Publication Date
EP1350101A2 true EP1350101A2 (fr) 2003-10-08

Family

ID=7670432

Family Applications (1)

Application Number Title Priority Date Filing Date
EP01985910A Withdrawn EP1350101A2 (fr) 2001-01-09 2001-12-20 Preparation tissulaire ou cellulaire morphometrique

Country Status (6)

Country Link
US (1) US20040072281A1 (fr)
EP (1) EP1350101A2 (fr)
JP (1) JP2004520034A (fr)
AU (1) AU2002235799A1 (fr)
DE (1) DE10101319A1 (fr)
WO (1) WO2002055680A2 (fr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5069374A (fr) * 1973-10-24 1975-06-10
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
DE3843534A1 (de) * 1988-12-23 1990-07-12 Basf Ag Neue tnf-polypeptide
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
WO1998006390A1 (fr) * 1996-08-13 1998-02-19 Marigen S.A. Concentres spontanement dispersibles d'esters de sterols et de derives de vitamine d a effet antiviral, virucide et/ou parasiticide

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO02055680A2 *

Also Published As

Publication number Publication date
US20040072281A1 (en) 2004-04-15
DE10101319A1 (de) 2002-07-18
WO2002055680A3 (fr) 2002-10-31
WO2002055680A2 (fr) 2002-07-18
AU2002235799A1 (en) 2002-07-24
JP2004520034A (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
Peters et al. Smooth and sparsely‐spined stellate cells in the visual cortex of the rat: A study using a combined Golgi‐electron microscope technique
WO2015135893A1 (fr) Obtention de cultures neuronales spécifiques à une région cérébrale à partir de cultures tissulaires tridimensionnelles de cellules souches
DE10014685A1 (de) Verfahren zur Identifizierung von zellspezifischen Zielstrukturen
WO2011124317A1 (fr) Procédé histologique
DE69228055T2 (de) Ein gewebekulturverfahren für haut im natürlichen zustand
DE69819696T2 (de) Verfahren zum nachweis beta-amyloid-reduzierenden-agenzien
EP3394610B1 (fr) Procédé de sexage in ovo de poussins
DE69736167T2 (de) Verfahren zur Bewertung der Schäden, die durch UV-A in der Haut hervorgerufen werden
EP1350101A2 (fr) Preparation tissulaire ou cellulaire morphometrique
WO2001054707A2 (fr) Utilisation d'au moins un inhibiteur d'aminopeptidase
DE69429669T2 (de) Drei reagenzien umfassendes gram-färbeverfahren und -kit
DE69528731T2 (de) Verwendung eines Inhibitors für Serin/Threonin Protein Phosphatasen zur Induzierung der Kondensation unreifer Chromosomen
DE2424955B2 (de) Verfahren zum Herstellen eines mikroskopischen Objektträgers
EP2795318B1 (fr) Modèle de peau à gène rapporteur 3d in vitro
DE10155130A1 (de) Verfahren zur Isolierung von Neuronen
Tyrer et al. Spatial distribution of synapses onto thoracic motor neurones in locusts
DE2019778A1 (de) Verfahren zur Bestimmung der Zellverteilung von Ribonukleinsaeuren
EP1136823A2 (fr) Méthode pour l'identification et l'enrichissement des structures cibles spécifiques aux cellules
DE102006045607A1 (de) Verfahren zur räumlich hochauflösenden Untersuchung von einer mit einer fluoreszierenden Substanz markierten Struktur einer Probe
Letinsky Staining normal and experimental motor nerve terminals with tetrazolium salts
WO2003005023A2 (fr) Procede pour determiner des interactions entre des keratinocytes et des neurones
EP1407263B1 (fr) Procede de detection extracorporelle qualitative et/ou quantitative de substances neurotoxiques dans le plasma sanguin d'un individu
EP1454144A1 (fr) Procede de determination analytique quantitative d'agglomerats
DE102009045924B4 (de) Verfahren und Testsystem zur Untersuchung des Einflusses von Substanzen auf Nervenfasern von Projektionssystemen
DE102007056198B4 (de) Beurteilung der Wirkung eines endogenen oder exogenen Einflusses auf Epithelgewebe durch Kartierung des Gewebes mittels markierter histologischer Gewebeschnitte

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030612

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20031222